Check Cap (NASDAQ:CHEK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “
Separately, HC Wainwright decreased their price objective on shares of Check Cap from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Tuesday, November 28th.
A hedge fund recently bought a new stake in Check Cap stock. Armistice Capital LLC acquired a new position in Check Cap Ltd (NASDAQ:CHEK) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 748,000 shares of the medical research company’s stock, valued at approximately $651,000. Armistice Capital LLC owned approximately 3.88% of Check Cap as of its most recent SEC filing. Institutional investors and hedge funds own 17.10% of the company’s stock.
About Check Cap
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.